Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berotralstat in hereditary angioedema
NCT04933721Phase 3Enrolling by invitation
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2021
- Primary completion
- Aug 2031
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Treatment-related Treatment-Emergent Adverse Events at 240 weeks, Serious Adverse Events at 240 weeks and 3 more. Started Jul 2021; status: enrolling by invitation.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04933721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933721.